leadf
logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics directors show confidence in oncology strategy with on-market purchases

The company’s paxalisib treatment for malignant glioma has been recently granted Orphan Drug Designation by the US FDA.

Kazia Therapeutics Ltd - Kazia Therapeutics directors demonstrate confidence in the company’s oncology strategy with on-market share purchases
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer

Kazia Therapeutics Ltd (ASX:KZA) directors Dr James Garner and Iain Ross have demonstrated their confidence in the company’s oncology strategy with the purchase of shares on-market.

Chief executive officer Dr James Garner acquired 25,000 ordinary shares on August 27, increasing the total amount of securities held after the change to 300,000 shares.

Chairman and non-executive director Iain Ross purchased 20,000 shares, increasing the number of securities held after the change to 820,001 shares.

US FDA orphan drug designation to paxalisib

The company’s paxalisib treatment for malignant glioma has been recently granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).

The treatment includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.

ODD is a special status accorded to drugs which are considered promising potential treatments for rare (orphan) diseases, generally defined as those which affect less than 200,000 cases per annum in the United States.

It can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), extending the effective life of a commercial product.

Quick facts: Kazia Therapeutics Ltd

Price: 0.835 AUD

ASX:KZA
Market: ASX
Market Cap: $96.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 08/21/2020

2 min read